P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy

摘要

We read with interest the paper by Cuisset et al. (1) on the subject of very low on-treatment platelet reactivity (VLTPR) as a measure of hyper-response to thienopyridines. The efficacy of platelet inhibition as evaluated by vasodilator-stimulated phosphoprotein (VASP) phosphorylation flow cytometry assay was used as a predictor of non-access site-related bleeding events. The absence of information regarding the periprocedural use of aspirin and the related cyclo-oxygenase-dependent platelet inhibitory response is a major drawback of the present study (1).